Skip to main content
Fig. 4 | BMC Immunology

Fig. 4

From: CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling

Fig. 4

Pre-treatment with CXCR3-specific antagonist AMG487 abrogates the CXCL9-up-regulated PD-L1 expression in T24 cells. T24 cells were pre-treated with, or without, AMG487 (1 μM) for 2 h and treated with the supernatants of co-cultured TADCs or CXCL9 (100 ng/mL) for 72 h. The levels of PD-L1 in individual groups of T24 cells were quantified by flow cytometry using specific anti-PD-L1. Data are representative flow histograms or expressed as the mean ± SD of each group of cells from three separate experiments. a, c Flow cytometry analysis. b, d Quantitative analysis. *P < 0.05, **P < 0.01

Back to article page